: Aurobindo Pharma Monday said its consolidated net profit after its Joint Venture share and minority interest for the quarter ended September 30 was down by 21.7 per cent to Rs 611.40 crore against Rs 781.10 crore in the second quarter of the last fiscal.
A company press release said the drug maker clocked Rs 4,751.40 crore revenues from operations, up 7.1 per cent when compared to Rs 4,435.90 crore during the same quarter in FY18.
N Govindarajan, Managing Director of the company said: "We have delivered a healthy quarter in terms of both financial performance and developments in differentiated portfolio.
Our revenues increased by seven per cent YoY, EBITDA ( earnings before interest, tax, depreciation and amortisation) and margin for the quarter was at 21.6 per cent and net profit after JV share and minority interest was at Rs 611.40 crore."
The company filed two Abbreviated New Drug Applications (ANDA) in dermatology and one nasal with US Food and Drug Administration in the first half of the fiscal, he said.
Revenues from formulations for the quarter posted a growth of 7.4 per cent over the same quarter to Rs 3,934.8 crore and and accounted for 82.8 per cent of total revenues, it said.
The US sales witnessed a 6.1 per cent growth to Rs 2,226.80 crore, compared to Rs 2,098. 9 crore in Q2FY18.
But on on a constant currency basis, sales declined by 2.6 per cent YoY, he said.
The USA accounted for 46.9 per cent of total revenues.
The company filed 25 ANDAs with USFDA, including eight ANDAs for injectable products and received final approval for 13 ANDAs and tentative approval for two ANDAs during the quarter.
Disclaimer: No Business Standard Journalist was involved in creation of this content
